iMetabolic Biopharma Corporation
iMetabolic Biopharma is at the forefront of a medical revolution, pioneering the future of healthcare with groundbreaking TechBio AI technology. The company's mission is to address obesity-related health crises and redefine therapeutics through innovative computational approaches, strategic partnerships, and community engagement. Their focus includes developing safer, more effective, and affordable treatments for cardiovascular, neurodegenerative, and metabolic diseases, aiming to transform the landscape of medicine and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
iMetabolic Biopharma Corporation
Tempe, Arizona, United States, North America
Products
iMBP-XR-02/03
Engineered binding agents designed to recognize markers on small dense LDL (sdLDL) particles and include a bioactive domain that facilitates hepatic uptake to clear these particles from circulation.
iMBP-AE-201
Multi‑domain recombinant fusion protein developed to recognize features of chylomicron and VLDL remnant particles and restore metabolic competency to promote particle clearance, described as a post‑expression protein therapeutic approach.
iMBP-AD-500
Computationally engineered therapeutic candidate intended to address lipid metabolism, neuroinflammation, and protein plaque pathology in mild cognitive impairment and Alzheimer’s disease; designed with delivery enhancements for blood–brain barrier transport.
iMBP-001/150
Metabolic inhibitor antagonist candidates intended to preserve lipase activity to address Familial Chylomicronemia Syndrome (FCS) and acute pancreatitis.
iMBP-XR-02/03
Engineered binding agents designed to recognize markers on small dense LDL (sdLDL) particles and include a bioactive domain that facilitates hepatic uptake to clear these particles from circulation.
iMBP-AE-201
Multi‑domain recombinant fusion protein developed to recognize features of chylomicron and VLDL remnant particles and restore metabolic competency to promote particle clearance, described as a post‑expression protein therapeutic approach.
iMBP-AD-500
Computationally engineered therapeutic candidate intended to address lipid metabolism, neuroinflammation, and protein plaque pathology in mild cognitive impairment and Alzheimer’s disease; designed with delivery enhancements for blood–brain barrier transport.
iMBP-001/150
Metabolic inhibitor antagonist candidates intended to preserve lipase activity to address Familial Chylomicronemia Syndrome (FCS) and acute pancreatitis.
Expertise Areas
- Computational drug discovery and molecular design
- Protein therapeutic engineering and biologics design
- Preclinical R&D for cardiometabolic and neurodegenerative diseases
- Blood–brain barrier delivery strategies
Key Technologies
- Machine learning and AI for drug discovery
- Physics‑based biological simulations
- In‑silico molecular design
- Recombinant fusion protein engineering
News & Updates
In April, iMBP moved to the Center of Entrepreneurial Innovation (CEI) in Phoenix, Arizona, with a dedicated wet lab and office space to support drug discovery efforts.
In December, iMBP established Team Everest for the XPrize Healthspan competition, a global challenge to revolutionize human aging.
In December, Dr. Kiernan’s journey in founding and developing iMBP was highlighted in Grit Daily.
In December, the Decoding Health Podcast milestone was celebrated, with Dr. Kiernan discussing the benefits of the ketogenic diet.
In November, Dr. Kiernan participated in the Beyond Activ Conference in NYC, discussing integrating wellness and medicine.
In November, iMBP was featured in VentureBeat, highlighting their second NIH SBIR grant award.
In April, iMBP moved to the Center of Entrepreneurial Innovation (CEI) in Phoenix, Arizona, with a dedicated wet lab and office space to support drug discovery efforts.
In December, iMBP established Team Everest for the XPrize Healthspan competition, a global challenge to revolutionize human aging.
In December, Dr. Kiernan’s journey in founding and developing iMBP was highlighted in Grit Daily.
In December, the Decoding Health Podcast milestone was celebrated, with Dr. Kiernan discussing the benefits of the ketogenic diet.
In November, Dr. Kiernan participated in the Beyond Activ Conference in NYC, discussing integrating wellness and medicine.
In November, iMBP was featured in VentureBeat, highlighting their second NIH SBIR grant award.